,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes,Lead_proteins
0,prerank,Striated Muscle Contraction,-0.9259259259259258,-1.652061485418761,0.004347826086956522,0.026158182138453407,0.012,3/3,14.04%,TMOD4;TMOD3;TMOD1,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
1,prerank,Retinoid cycle disease events,0.9818181818181817,1.3750692979185195,0.011477761836441894,0.2975564700228283,0.467,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
2,prerank,Diseases of the neuronal system,0.9818181818181817,1.3750692979185195,0.011477761836441894,0.2975564700228283,0.467,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
3,prerank,Diseases associated with visual transduction,0.9818181818181817,1.3750692979185195,0.011477761836441894,0.2975564700228283,0.467,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
4,prerank,The canonical retinoid cycle in rods (twilight vision),0.9818181818181817,1.3750692979185195,0.011477761836441894,0.2975564700228283,0.467,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
5,prerank,Formation of the cornified envelope,-1.0,-1.3348984198645604,0.03409090909090909,0.618259534084904,0.604,1/1,3.51%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
6,prerank,Developmental Biology,-1.0,-1.3348984198645604,0.03409090909090909,0.618259534084904,0.604,1/1,3.51%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
7,prerank,Keratinization,-1.0,-1.3348984198645604,0.03409090909090909,0.618259534084904,0.604,1/1,3.51%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
8,prerank,Alanine metabolism,-0.8181818181818181,-1.3113804473754558,0.1162079510703364,1.0,0.834,2/2,22.81%,GPT;GPT2,A0A024R6R2;B3KR40;B4DPT5;B4E1C6;P24298;Q8TD30;Q8TD30-2;A0A024R6R2;B3KR40;B4DPT5;B4E1C6;P24298;Q8TD30;Q8TD30-2
9,prerank,Metabolism of proteins,0.7513350961924542,1.3087933367653677,0.05070993914807302,1.0,0.866,7/11,26.32%,TTR;TSPAN14;SERPIND1;ITIH2;AHSG;APOA1;KNG1,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
10,prerank,Non-integrin membrane-ECM interactions,1.0,1.3077718259562083,0.022132796780684104,0.976054057030718,0.868,1/1,1.75%,TTR,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2
11,prerank,Molecules associated with elastic fibres,0.982142857142857,1.3053340337137673,0.056338028169014086,0.7809684008170131,0.885,1/1,3.51%,MFAP4,A0A024QZ34;K7ES70;P55083;P55083-2
12,prerank,Elastic fibre formation,0.982142857142857,1.3053340337137673,0.056338028169014086,0.7809684008170131,0.885,1/1,3.51%,MFAP4,A0A024QZ34;K7ES70;P55083;P55083-2
13,prerank,Retinoid metabolism disease events,0.9642857142857143,1.2667314230208833,0.10766045548654245,1.0,0.984,1/1,5.26%,RBP4,A0A0C4DGV7;P02753;Q5VY30
14,prerank,Metabolism of vitamins and cofactors,0.830470911267932,1.2607549737813903,0.1111111111111111,1.0,0.99,2/4,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
15,prerank,Formation of the Editosome,-0.9464285714285714,-1.258971736705094,0.1232876712328767,1.0,0.974,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
16,prerank,mRNA Editing: C to U Conversion,-0.9464285714285714,-1.258971736705094,0.1232876712328767,1.0,0.974,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
17,prerank,mRNA Editing,-0.9464285714285714,-1.258971736705094,0.1232876712328767,1.0,0.974,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
18,prerank,Retinoid metabolism and transport,0.8440993481875336,1.2434787512931913,0.13032581453634084,1.0,0.995,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
19,prerank,Sensory Perception,0.8440993481875336,1.2434787512931913,0.13032581453634084,1.0,0.995,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
20,prerank,Metabolism of fat-soluble vitamins,0.8440993481875336,1.2434787512931913,0.13032581453634084,1.0,0.995,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
21,prerank,Visual phototransduction,0.8440993481875336,1.2434787512931913,0.13032581453634084,1.0,0.995,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
22,prerank,Hemostasis,0.7051583015604372,1.2305471422995866,0.11280487804878049,1.0,1.0,10/11,40.35%,CLEC3B;CLU;SERPIND1;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;P05546;Q8IVC0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
23,prerank,Metabolism,0.6759243636351248,1.2192373964128098,0.10020040080160321,1.0,1.0,7/18,28.07%,TTR;RBP4;PRELP;GATM;DDAH1;APOA1;LUM,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30;P51888;Q6FHG6;Q7Z4B2;A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3;B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;P51884;Q53FV4
24,prerank,RHOBTB GTPase Cycle,-0.9107142857142857,-1.2096153846153836,0.21621621621621623,1.0,0.996,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
25,prerank,RND3 GTPase cycle,-0.9107142857142857,-1.2096153846153836,0.21621621621621623,1.0,0.996,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
26,prerank,RHOBTB2 GTPase cycle,-0.9107142857142857,-1.2096153846153836,0.21621621621621623,1.0,0.996,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
27,prerank,"Platelet activation, signaling and aggregation",0.7083333333333334,1.2074844807254872,0.13786008230452676,1.0,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
28,prerank,Platelet degranulation,0.7083333333333334,1.2074844807254872,0.13786008230452676,1.0,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
29,prerank,Response to elevated platelet cytosolic Ca2+,0.7083333333333334,1.2074844807254872,0.13786008230452676,1.0,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
30,prerank,Extracellular matrix organization,0.75,1.193167356071235,0.1728395061728395,1.0,1.0,5/5,31.58%,TTR;MFAP4;COL18A1;LUM;A2M,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A024QZ34;K7ES70;P55083;P55083-2;D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;P51884;Q53FV4;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
31,prerank,Amyloid fiber formation,0.8044415769828186,1.185994181687244,0.2225031605562579,1.0,1.0,2/3,8.77%,TTR;TSPAN14,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3
32,prerank,Antimicrobial peptides,0.8928571428571428,1.1813912533020252,0.2546583850931677,1.0,1.0,1/1,12.28%,CLU,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0
33,prerank,Terminal pathway of complement,0.8928571428571428,1.1813912533020252,0.2546583850931677,1.0,1.0,1/1,12.28%,CLU,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0
34,prerank,Viral Infection Pathways,-0.7454545454545454,-1.1760206520699865,0.23,1.0,0.998,2/2,29.82%,ATP6V1H;ATP1A1,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
35,prerank,Disease,0.6813387947414352,1.1721328028341533,0.19390862944162437,1.0,1.0,3/10,7.02%,TTR;RBP4;PRELP,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30;P51888;Q6FHG6;Q7Z4B2
36,prerank,Common Pathway of Fibrin Clot Formation,0.875,1.169626914763651,0.26968503937007876,1.0,1.0,1/1,14.04%,SERPIND1,P05546;Q8IVC0
37,prerank,Post-translational protein phosphorylation,0.7103896198163804,1.1662778229668753,0.23068669527896996,1.0,1.0,5/6,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
38,prerank,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.7103896198163804,1.1662778229668753,0.23068669527896996,1.0,1.0,5/6,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
39,prerank,Post-translational protein modification,0.6888710408037821,1.1536935021223436,0.235480464625132,1.0,1.0,5/7,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
40,prerank,Collagen formation,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
41,prerank,Laminin interactions,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
42,prerank,Activation of Matrix Metalloproteinases,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
43,prerank,Collagen degradation,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
44,prerank,Collagen biosynthesis and modifying enzymes,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
45,prerank,Collagen chain trimerization,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
46,prerank,Assembly of collagen fibrils and other multimeric structures,0.8571428571428572,1.134461833280102,0.31467181467181465,1.0,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
47,prerank,ROS and RNS production in phagocytes,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
48,prerank,HIV Infection,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
49,prerank,Infection with Mycobacterium tuberculosis,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
50,prerank,Signaling by Insulin receptor,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
51,prerank,Insulin receptor recycling,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
52,prerank,Host Interactions of HIV factors,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
53,prerank,Signaling by Receptor Tyrosine Kinases,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
54,prerank,Amino acids regulate mTORC1,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
55,prerank,Bacterial Infection Pathways,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
56,prerank,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
57,prerank,Nef Mediated CD4 Down-regulation,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
58,prerank,Cellular response to starvation,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
59,prerank,Transferrin endocytosis and recycling,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
60,prerank,Nef Mediated CD8 Down-regulation,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
61,prerank,The role of Nef in HIV-1 replication and disease pathogenesis,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
62,prerank,Response of Mtb to phagocytosis,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
63,prerank,Suppression of phagosomal maturation,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
64,prerank,Blockage of phagosome acidification,-0.8571428571428571,-1.1256399005411735,0.34303534303534305,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
65,prerank,Ketone body metabolism,-0.8392857142857142,-1.114362428324384,0.3435700575815739,1.0,1.0,1/1,19.30%,ACSS3,A0A0B4J1R2;F8VZB4;Q9H6R3;Q9H6R3-2
66,prerank,Synthesis of Ketone Bodies,-0.8392857142857142,-1.114362428324384,0.3435700575815739,1.0,1.0,1/1,19.30%,ACSS3,A0A0B4J1R2;F8VZB4;Q9H6R3;Q9H6R3-2
67,prerank,Creatine metabolism,0.8214285714285714,1.1014575052053757,0.3675889328063241,1.0,1.0,1/1,19.30%,GATM,A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3
68,prerank,Neutrophil degranulation,0.6857517222645296,1.0773988580813965,0.36054421768707484,1.0,1.0,4/5,29.82%,TTR;TSPAN14;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
69,prerank,Metabolism of nitric oxide: NOS3 activation and regulation,0.8035714285714286,1.0583661322837656,0.43673469387755104,1.0,1.0,1/1,21.05%,DDAH1,B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2
70,prerank,eNOS activation,0.8035714285714286,1.0583661322837656,0.43673469387755104,1.0,1.0,1/1,21.05%,DDAH1,B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2
71,prerank,Innate Immune System,0.620495410429655,1.050183173790882,0.40763673890608876,1.0,1.0,5/9,29.82%,TTR;TSPAN14;CLU;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
72,prerank,Immune System,0.620495410429655,1.050183173790882,0.40763673890608876,1.0,1.0,5/9,29.82%,TTR;TSPAN14;CLU;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
73,prerank,Translation,-0.6545454545454545,-1.0483498197282053,0.41904761904761906,1.0,1.0,2/2,38.60%,PTCD3;EPRS1,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2;B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
74,prerank,Integrin cell surface interactions,0.7454545454545456,1.046930105995294,0.40575539568345326,1.0,1.0,2/2,28.07%,COL18A1;LUM,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;P51884;Q53FV4
75,prerank,Metabolism of RNA,-0.6545454545454545,-1.0399373531714953,0.4186746987951807,1.0,1.0,2/2,38.60%,APOBEC2;EPRS1,B4DUL0;Q9Y235;B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
76,prerank,Muscle contraction,-0.5,-1.038648911984411,0.3902439024390244,1.0,1.0,5/5,56.14%,TMOD4;TMOD3;TMOD1;ATP1A1;ATP2A2,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
77,prerank,Keratan sulfate/keratin metabolism,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
78,prerank,Defective ST3GAL3 causes MCT12 and EIEE15,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
79,prerank,Diseases associated with glycosaminoglycan metabolism,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
80,prerank,Keratan sulfate degradation,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
81,prerank,Glycosaminoglycan metabolism,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
82,prerank,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
83,prerank,Diseases of metabolism,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
84,prerank,Keratan sulfate biosynthesis,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
85,prerank,Diseases of glycosylation,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
86,prerank,Defective CHST6 causes MCDC1,0.7454545454545454,1.0369821555426506,0.4518950437317784,1.0,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
87,prerank,Protein localization,-0.7678571428571428,-1.0326747356838721,0.4760956175298805,1.0,1.0,1/1,26.32%,CHCHD4,A0A024R2F8;A0A024R2I5;Q8N4Q1;Q8N4Q1-2
88,prerank,Mitochondrial protein import,-0.7678571428571428,-1.0326747356838721,0.4760956175298805,1.0,1.0,1/1,26.32%,CHCHD4,A0A024R2F8;A0A024R2I5;Q8N4Q1;Q8N4Q1-2
89,prerank,Infectious disease,-0.5740740740740741,-1.0274492626660827,0.4008810572687225,1.0,1.0,3/3,47.37%,ATP6V1H;ATP1A1;SUGT1,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
90,prerank,Metabolism of carbohydrates,0.6967110985312106,1.0265543378975268,0.45226130653266333,1.0,1.0,2/3,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
91,prerank,Intrinsic Pathway of Fibrin Clot Formation,0.6603773584905661,1.0234262470616002,0.43888242142025613,1.0,1.0,4/4,38.60%,SERPIND1;KNG1;A2M;SERPING1,P05546;Q8IVC0;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
92,prerank,Formation of Fibrin Clot (Clotting Cascade),0.6603773584905661,1.0234262470616002,0.43888242142025613,1.0,1.0,4/4,38.60%,SERPIND1;KNG1;A2M;SERPING1,P05546;Q8IVC0;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
93,prerank,Fatty acid metabolism,-0.5283018867924528,-1.0172764227642275,0.45454545454545453,1.0,1.0,4/4,52.63%,CPT1A;ACSL5;ACSL1;ACSL6,A0A024R5F4;B2RAQ8;P50416;P50416-2;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
94,prerank,Chylomicron assembly,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
95,prerank,ABC-family proteins mediated transport,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
96,prerank,Scavenging by Class B Receptors,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
97,prerank,Defective ABCA1 causes TGD,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
98,prerank,ABC transporter disorders,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
99,prerank,Scavenging by Class A Receptors,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
100,prerank,HDL clearance,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
101,prerank,Heme signaling,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
102,prerank,Plasma lipoprotein remodeling,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
103,prerank,HDL remodeling,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
104,prerank,Chylomicron remodeling,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
105,prerank,ABC transporters in lipid homeostasis,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
106,prerank,Plasma lipoprotein clearance,0.7678571428571429,1.00727951469902,0.5179282868525896,0.8954025786092401,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
107,prerank,Degradation of the extracellular matrix,0.709090909090909,1.0053497707788284,0.47788873038516405,0.8858402897854207,1.0,2/2,31.58%,COL18A1;A2M,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
108,prerank,"Plasma lipoprotein assembly, remodeling, and clearance",0.709090909090909,1.0018909527001945,0.502906976744186,0.8619151289265357,1.0,2/2,31.58%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
109,prerank,Plasma lipoprotein assembly,0.709090909090909,1.0018909527001945,0.502906976744186,0.8619151289265357,1.0,2/2,31.58%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
110,prerank,HDL assembly,0.709090909090909,1.0018909527001945,0.502906976744186,0.8619151289265357,1.0,2/2,31.58%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
111,prerank,G alpha (i) signalling events,0.75,0.9884401050062173,0.547945205479452,0.8397263255787826,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
112,prerank,Peptide ligand-binding receptors,0.75,0.9884401050062173,0.547945205479452,0.8397263255787826,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
113,prerank,Class A/1 (Rhodopsin-like receptors),0.75,0.9884401050062173,0.547945205479452,0.8397263255787826,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
114,prerank,GPCR ligand binding,0.75,0.9884401050062173,0.547945205479452,0.8397263255787826,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
115,prerank,G alpha (q) signalling events,0.75,0.9884401050062173,0.547945205479452,0.8397263255787826,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
116,prerank,Gene expression (Transcription),-0.6181818181818182,-0.9817436661698961,0.4645161290322581,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
117,prerank,RNA Polymerase II Transcription,-0.6181818181818182,-0.9817436661698961,0.4645161290322581,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
118,prerank,Generic Transcription Pathway,-0.6181818181818182,-0.9817436661698961,0.4645161290322581,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
119,prerank,SARS-CoV Infections,-0.7321428571428571,-0.9774176169525012,0.5386064030131826,1.0,1.0,1/1,29.82%,ATP1A1,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
120,prerank,Potential therapeutics for SARS,-0.7321428571428571,-0.9774176169525012,0.5386064030131826,1.0,1.0,1/1,29.82%,ATP1A1,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
121,prerank,Circadian Clock,-0.6,-0.9652421652421654,0.512987012987013,1.0,1.0,2/2,43.86%,NAMPT;CPT1A,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R5F4;B2RAQ8;P50416;P50416-2
122,prerank,ECM proteoglycans,0.7321428571428572,0.953673192479163,0.6145833333333334,0.9225983488756827,1.0,1/1,28.07%,LUM,P51884;Q53FV4
123,prerank,Binding and Uptake of Ligands by Scavenger Receptors,0.6727272727272726,0.9418993419224825,0.6,0.9215567929232248,1.0,2/2,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
124,prerank,Scavenging of heme from plasma,0.6727272727272726,0.9418993419224825,0.6,0.9215567929232248,1.0,2/2,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
125,prerank,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
126,prerank,NPAS4 regulates expression of target genes,-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
127,prerank,Transcriptional Regulation by NPAS4,-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
128,prerank,Nicotinamide salvaging,-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
129,prerank,Nicotinate metabolism,-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
130,prerank,Metabolism of water-soluble vitamins and cofactors,-0.6964285714285714,-0.9393765263611561,0.5904572564612326,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
131,prerank,Metabolism of amino acids and derivatives,0.6079633979589499,0.9384649116693872,0.5899880810488677,0.9239813850656295,1.0,1/4,19.30%,GATM,A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3
132,prerank,Fatty acyl-CoA biosynthesis,-0.5185185185185185,-0.9272985333543603,0.5904761904761905,1.0,1.0,3/3,52.63%,ACSL5;ACSL1;ACSL6,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
133,prerank,Synthesis of very long-chain fatty acyl-CoAs,-0.5185185185185185,-0.9272985333543603,0.5904761904761905,1.0,1.0,3/3,52.63%,ACSL5;ACSL1;ACSL6,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
134,prerank,Signaling by GPCR,0.6545454545454544,0.9141594566491057,0.6479885057471264,0.9574372221554728,1.0,2/2,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
135,prerank,GPCR downstream signalling,0.6545454545454544,0.9141594566491057,0.6479885057471264,0.9574372221554728,1.0,2/2,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
136,prerank,Mitochondrial translation termination,-0.6785714285714285,-0.9045882127087735,0.6754032258064516,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
137,prerank,Mitochondrial translation initiation,-0.6785714285714285,-0.9045882127087735,0.6754032258064516,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
138,prerank,Mitochondrial translation,-0.6785714285714285,-0.9045882127087735,0.6754032258064516,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
139,prerank,Mitochondrial translation elongation,-0.6785714285714285,-0.9045882127087735,0.6754032258064516,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
140,prerank,Regulation of Complement cascade,0.6363636363636364,0.8893299996124235,0.6923076923076923,0.9914389431129895,1.0,2/2,38.60%,CLU;SERPING1,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
141,prerank,Complement cascade,0.6363636363636364,0.8893299996124235,0.6923076923076923,0.9914389431129895,1.0,2/2,38.60%,CLU;SERPING1,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
142,prerank,Vesicle-mediated transport,0.5986844835747196,0.8865760933974399,0.6755386565272496,0.9905742422930015,1.0,2/3,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
143,prerank,tRNA Aminoacylation,-0.6428571428571428,-0.8682685829777669,0.7057728119180633,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
144,prerank,Cytosolic tRNA aminoacylation,-0.6428571428571428,-0.8682685829777669,0.7057728119180633,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
145,prerank,tRNA modification in the nucleus and cytosol,-0.6428571428571428,-0.8682685829777669,0.7057728119180633,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
146,prerank,tRNA processing,-0.6428571428571428,-0.8682685829777669,0.7057728119180633,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
147,prerank,Selenoamino acid metabolism,-0.6428571428571428,-0.8682685829777669,0.7057728119180633,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
148,prerank,Cellular responses to stress,0.589230604209887,0.8626372150181468,0.735705209656925,1.0,1.0,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
149,prerank,Cellular responses to stimuli,0.589230604209887,0.8626372150181468,0.735705209656925,1.0,1.0,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
150,prerank,Ion channel transport,-0.48148148148148145,-0.8599221789883263,0.7104072398190046,1.0,1.0,3/3,56.14%,ATP6V1H;ATP1A1;ATP2A2,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
151,prerank,RHOC GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
152,prerank,G alpha (12/13) signalling events,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
153,prerank,RHOA GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
154,prerank,p75 NTR receptor-mediated signalling,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
155,prerank,RAC3 GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
156,prerank,RAC2 GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
157,prerank,Death Receptor Signaling,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
158,prerank,NRAGE signals death through JNK,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
159,prerank,CDC42 GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
160,prerank,RAC1 GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
161,prerank,"Cell death signalling via NRAGE, NRIF and NADE",0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
162,prerank,RHOB GTPase cycle,0.6428571428571429,0.8475086290822195,0.7349624060150376,0.9193462393367776,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
163,prerank,Disorders of transmembrane transporters,0.6000000000000001,0.8426017507547473,0.748898678414097,0.9229761736236101,1.0,2/2,42.11%,APOA1;CP,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
164,prerank,PPARA activates gene expression,0.555134624067057,0.8332809095205805,0.7537878787878788,0.9245566444138306,1.0,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
165,prerank,Regulation of lipid metabolism by PPARalpha,0.555134624067057,0.8332809095205805,0.7537878787878788,0.9245566444138306,1.0,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
166,prerank,Glycogen metabolism,-0.625,-0.8299277703858581,0.7735470941883767,1.0,1.0,1/1,40.35%,PYGM,A0A0M4FEM1;B2RB32;B4DRQ4;B4DRW6;P11217;P11217-2
167,prerank,Glycogen breakdown (glycogenolysis),-0.625,-0.8299277703858581,0.7735470941883767,1.0,1.0,1/1,40.35%,PYGM,A0A0M4FEM1;B2RB32;B4DRQ4;B4DRW6;P11217;P11217-2
168,prerank,Cytoprotection by HMOX1,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
169,prerank,Respiratory electron transport,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
170,prerank,Cellular response to chemical stress,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
171,prerank,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
172,prerank,Transcriptional Regulation by TP53,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
173,prerank,TP53 Regulates Metabolic Genes,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
174,prerank,The citric acid (TCA) cycle and respiratory electron transport,-0.6071428571428571,-0.8189247311827955,0.7559523809523809,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
175,prerank,Diseases of hemostasis,0.625,0.8152324614104821,0.8154761904761905,0.9311369211029223,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
176,prerank,Defective SERPING1 causes hereditary angioedema,0.625,0.8152324614104821,0.8154761904761905,0.9311369211029223,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
177,prerank,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.625,0.8152324614104821,0.8154761904761905,0.9311369211029223,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
178,prerank,Signaling by Nuclear Receptors,-0.5892857142857143,-0.7923486956931924,0.8153241650294696,1.0,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
179,prerank,Signaling by Retinoic Acid,-0.5892857142857143,-0.7923486956931924,0.8153241650294696,1.0,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
180,prerank,RORA activates gene expression,-0.5892857142857143,-0.7923486956931924,0.8153241650294696,1.0,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
181,prerank,Carnitine metabolism,-0.5892857142857143,-0.7923486956931924,0.8153241650294696,1.0,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
182,prerank,Transport of small molecules,0.48352377215996334,0.783823073062421,0.8428571428571429,0.9715610441059063,1.0,4/6,47.37%,APOA1;A2M;CP;ATP2A2,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2;P16615-2
183,prerank,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.5568727970027639,0.7740763143847311,0.8374455732946299,0.9613710774087141,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
184,prerank,Signaling by Rho GTPases,0.5568727970027639,0.7740763143847311,0.8374455732946299,0.9613710774087141,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
185,prerank,RHO GTPase cycle,0.5568727970027639,0.7740763143847311,0.8374455732946299,0.9613710774087141,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
186,prerank,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
187,prerank,"Transport of bile salts and organic acids, metal ions and amine compounds",0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
188,prerank,Metal ion SLC transporters,0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
189,prerank,SLC-mediated transmembrane transport,0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
190,prerank,SLC transporter disorders,0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
191,prerank,Defective CP causes aceruloplasminemia (ACERULOP),0.5892857142857143,0.76987987689864,0.8638297872340426,0.9220593018101065,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
192,prerank,DNA Repair,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
193,prerank,DNA Damage Recognition in GG-NER,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
194,prerank,Nucleotide Excision Repair,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
195,prerank,Membrane Trafficking,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
196,prerank,Transcription-Coupled Nucleotide Excision Repair (TC-NER),-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
197,prerank,Cargo recognition for clathrin-mediated endocytosis,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
198,prerank,Formation of TC-NER Pre-Incision Complex,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
199,prerank,Global Genome Nucleotide Excision Repair (GG-NER),-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
200,prerank,Neddylation,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
201,prerank,Clathrin-mediated endocytosis,-0.5714285714285714,-0.7589208006962577,0.8715596330275229,0.9870151283637362,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
202,prerank,Ion transport by P-type ATPases,-0.4727272727272727,-0.7411821549363817,0.903954802259887,0.9812257423508619,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
203,prerank,Cardiac conduction,-0.4727272727272727,-0.7411821549363817,0.903954802259887,0.9812257423508619,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
204,prerank,Ion homeostasis,-0.4727272727272727,-0.7411821549363817,0.903954802259887,0.9812257423508619,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
205,prerank,The NLRP3 inflammasome,-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
206,prerank,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
207,prerank,Parasitic Infection Pathways,-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
208,prerank,Cell recruitment (pro-inflammatory response),-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
209,prerank,Inflammasomes,-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
210,prerank,Purinergic signaling in leishmaniasis infection,-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
211,prerank,Leishmania infection,-0.5535714285714285,-0.7306763815125316,0.8994413407821229,0.9245055432006342,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
212,prerank,Pre-NOTCH Processing in Golgi,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
213,prerank,Signaling by NOTCH,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
214,prerank,Platelet calcium homeostasis,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
215,prerank,Reduction of cytosolic Ca++ levels,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
216,prerank,Platelet homeostasis,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
217,prerank,Pre-NOTCH Expression and Processing,0.5357142857142856,0.7008547008546998,0.9645232815964523,0.9675547884294559,1.0,1/1,47.37%,ATP2A2,P16615-2
218,prerank,Signal Transduction,0.4298419312602791,0.6963106524927853,0.938034188034188,0.9633515681396151,1.0,2/6,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
219,prerank,alpha-linolenic acid (ALA) metabolism,-0.5178571428571428,-0.6886827458256033,0.974609375,0.9537938171569491,1.0,1/1,50.88%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
220,prerank,Linoleic acid (LA) metabolism,-0.5178571428571428,-0.6886827458256033,0.974609375,0.9537938171569491,1.0,1/1,50.88%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
221,prerank,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,-0.5178571428571428,-0.6886827458256033,0.974609375,0.9537938171569491,1.0,1/1,50.88%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
222,prerank,Iron uptake and transport,0.46574412166789664,0.6507278039354638,0.9770114942528736,0.9923646046904613,1.0,1/2,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
223,prerank,Metabolism of lipids,0.37986297797726265,0.6166459662110574,0.9762419006479481,0.9927159678000721,1.0,5/6,59.65%,APOA1;ACSL6;ACSL1;ACSL5;CPT1A,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A0A024R5F4;B2RAQ8;P50416;P50416-2
